Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth

Anti-Cancer Drugs

Volumn 22, Issue 10, 2011, Pages 978-985

  Hilliard, Tyvette S ^a   Gaisina, Irina N ^a   Muehlbauer, Amanda G ^a   Gaisin, Arsen M ^a   Gallier, Franck ^a   Burdette, Joanna E ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

drug discovery; GSK3b; ovarian cancer; Wnt; xenograft

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CASPASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; MALEIMIDE; POLY(ADENOSINE DIPHOSPHATE RIBOSE);

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NICK END LABELING; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; TUMOR GROWTH; UPREGULATION;

ANIMALS; APOPTOSIS; BIOLOGICAL AVAILABILITY; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, SPRAGUE-DAWLEY; SERINE; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053653605     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834ac8fc     Document Type: Article

References (27)

1. Jemal A, Siegal R, Xu J, Ward E, CA A. Cancer Journal for Clinicians 2010; 60:277-300.
2. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel- carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96:1682-1691. (Pubitemid 39585637)
3. Cao Q, Lu X, Feng YJ. Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res 2006; 16:671-677. (Pubitemid 44091443)
4. Jeays-Ward K, Hoyle C, Brennan J, Dandonneau M, Alldus G, Capel B, et al. Endothelial and steroidogenic cell migration are regulated by WNT4 in the developing mammalian gonad. Development 2003; 130:3663-3670. (Pubitemid 37039072)
5. Yao HH, Matzuk MM, Jorgez CJ, Menke DB, Page DC, Swain A, et al. Follistatin operates downstream of Wnt4 in mammalian ovary organogenesis. Dev Dyn 2004; 230:210-215. (Pubitemid 38669583)
6. Gatcliffe TA, Monk BJ, Planutis K, Holcombe RF. Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer 2008; 18:954-962.
7. Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 2004; 3:479-487. (Pubitemid 38807530)
8. Roose J, Clevers H. TCF transcription factors: molecular switches in carcinogenesis. Biochim Biophys Acta 1999; 1424:M23-M37. (Pubitemid 29488713)
9. Cai G, Wang J, Xin X, Ke Z, Luo J. Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells. Int J Oncol 2007; 31:657-662.
10. Shakoori A, Mai W, Miyashita K, Yasumoto K, Takahashi Y, Ooi A, et al. Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci 2007; 98:1388-1393. (Pubitemid 47241761)
11. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, et al. Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 2004; 279:23477-23485. (Pubitemid 38685659)
12. Mamaghani S, Patel S, Hedley DW. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer 2009; 9:132-143.
13. Gaisina IN, Gallier F, Ougolkov AV, Kim KH, Kurome T, Guo S, et al. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem 2009; 52:1853-1863.
14. Pon YL, Wong AS. Gonadotropin-induced apoptosis in human ovarian surface epithelial cells is associated with cyclooxygenase-2 up-regulation via the beta-catenin/T-cell factor signaling pathway. Mol Endocrinol 2006; 20:3336-3350. (Pubitemid 44833574)
15. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther 2007; 6:1151-1158. (Pubitemid 46554586)
16. Hagopian GS, Mills GB, Khokhar AR, Bast RC Jr., Siddik ZH. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1 R, 2 R-diaminocyclohexane)(trans-diacetato)(dichloro)- platinum(IV). Clin Cancer Res 1999; 5:655-663. (Pubitemid 29131977)
17. Kozikowski AP, Gaisina IN, Petukhov PA, Sridhar J, King LT, Blond SY, et al. Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease. ChemMedChem 2006; 1: 256-266. (Pubitemid 43700306)
18. Kozikowski AP, Gaisina IN, Yuan H, Petukhov PA, Blond SY, Fedolak A, et al. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders. J Am Chem Soc 2007; 129: 8328-8332. (Pubitemid 47035143)
19. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A, Armas A. Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999; 155:527-536. (Pubitemid 29370402)
20. Do TV, Kubba LA, Antenos M, Rademaker AW, Sturgis CD, Woodruff TK. The role of activin A and Akt/GSK signaling in ovarian tumor biology. Endocrinology 2008; 149:3809-3816.
21. Rask K, Nilsson A, Brannstrom M, Carlsson P, Hellberg P, Janson PO, et al. Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer 2003; 89: 1298-1304. (Pubitemid 37363420)
22. Su HY, Lai HC, Lin YW, Liu CY, Chen CK, Chou YC, et al. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 2010; 127:555-567.
23. Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS. Inhibitory phospho-rylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 2003; 278: 33067-33077. (Pubitemid 37055753)
24. Ricken A, Lochhead P, Kontogiannea M, Farookhi R. Wnt signaling in the ovary: identification and compartmentalized expression of wnt-2, wnt-2b, and frizzled-4 mRNAs. Endocrinology 2002; 143: 2741-2749. (Pubitemid 34701338)
25. Karbova E, Davidson B, Metodiev K, Trope CG, Nesland JM. Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma. Int J Surg Pathol 2002; 10:175-180. (Pubitemid 34988511)
26. Badiglian Filho L, Oshima CT, De Oliveira Lima F, De Oliveira Costa H, De Sousa Damiao R, Gomes TS, et al. Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep 2009; 21:313-320.
27. Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB. Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 2004; 279: 39541-39554. (Pubitemid 39258221)